New clinical studies surrounding this compound, specifically the high-dose formulation referred to as ZPHC, suggest a impressive effect on body mass loss and linked chronic illnesses . Experts posit that this dual agonist , targeting both GLP-1 and GIP receptors , may represent a major breakthro